Clinical interpretation of cancer genomes for therapy selection and clinical hypothesis generation is an urgent and complex endeavor. A new study brings together a diverse set of data sources to automatically prioritize first- and second-order genomic alterations to provide a meaningful set of interpretations based on a patient’s molecular profile.
This is a preview of subscription content, log in via an institution to check access.
References
Chakravarty, D. & Solit, D. B. Nat. Rev. Genet. 22, 483–501 (2021).
Reardon, B. et al. Nat. Cancer https://doi.org/10.1038/s43018-021-00243-3 (2021).
Van Allen, E. M. et al. Nat. Med. 20, 682–688 (2014).
Tate, J. G. et al. Nucleic Acids Res. 47, D941–D947 (2019).
Chang, M. T. et al. Cancer Discov. 8, 174–183 (2018).
Yang, W. et al. Nucleic Acids Res. 41, D955–D961 (2013).
Ghandi, M. et al. Nature 569, 503–508 (2019).
Sicklick, J. K. et al. Nat. Med. 25, 744–750 (2019).
Tamborero, D. et al. Genome Med. 10, 25 (2018).
Chakravarty, D. et al. JCOPrecis. Oncol. 2017, PO.17.00011 (2017).
Griffith, M, et et al. Nat. Genet. 49, 170–174 (2017).
Huang, L. et al. J. Am. Med. Inform. Assoc. 24, 513–519 (2017).
Wagner, A. H. et al. Nat. Genet. 52, 448–457 (2020).
Ritter, D. I. et al. Genome Med. 8, 117 (2016).
Bielski, C. M. et al. Cancer Cell 34, 852–862.e4 (2018).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
Michael Berger discloses consulting fees from Eli Lilly and PetDx, unrelated to the manuscript.
Rights and permissions
About this article
Cite this article
Zehir, A., Berger, M.F. A quick guide for clinical oncology. Nat Cancer 2, 998–999 (2021). https://doi.org/10.1038/s43018-021-00273-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-021-00273-x
- Springer Nature America, Inc.